<DOC>
	<DOCNO>NCT01602770</DOCNO>
	<brief_summary>Qlaira combine oral contraceptive ( COC ) contain dienogest/estradiol valerate first oral contraceptive deliver estradiol . It recently approve Mexico . To evaluate clinical profile drug combination routine medical condition , post-authorization safety study require Mexican Health Authorities conduct Mexican woman . The study perform descriptive study , hypothesis test . The cohort consist 300 new user ( first-ever user switcher ) Qlaira routine medical condition . Subjects provide necessary information health-related event change health status Qlaira use . Primary variable incidence Adverse Events ( AE ) time point , whether related Qlaira least 2 year observation . In order comply criterion non-interventional study , woman inform study , ask participate include study Qlaira prescribed . Study patient follow-up do accordance common clinical practice describe Mexican Official Guidelines prescription Family Planning Methods ( NOM 005-SSA2-1993 ) .</brief_summary>
	<brief_title>Qlaira Post-authorization Safety Study Related Most Common Adverse Events Mexican Women Who Wish Avoid Pregnancy</brief_title>
	<detailed_description />
	<criteria>Healthy woman reproductive age : Seeking fertility control oral contraception least one year Able go back medical office regular basis Women risk parameter arterial venous thrombotic disease : Smoke , age 35 Deep vein thrombosis pulmonary embolism , past Cerebrovascular disease Coronary artery disease Thrombogenic valvular thrombogenic rhythm diseases heart Inherited acquire hypercoagulopathies Uncontrolled hypertension Diabetes vascular disease Headaches focal neurological symptom migraine headache without aura age 35 Undiagnosed abnormal genital bleed Breast cancer estrogen progestinsensitive cancer , past Liver tumor , benign malignant , liver disease Pregnancy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Oral contraceptive</keyword>
	<keyword>Adverse event</keyword>
	<keyword>Safety profile</keyword>
	<keyword>Contraceptive Agents</keyword>
</DOC>